Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Scott Randall Plotkin, M.D.,PH.D.

TitleAssociate Professor of Neurology
InstitutionMassachusetts General Hospital
DepartmentNeurology
AddressMassachusetts General Hospital
Pappas Ctr for Neuro-Oncology, Yawkey 9E
55 Fruit St
Boston MA 02114
Phone617/726-5533
Fax617/724-8769

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Nunes FP, Merker VL, Jennings D, Caruso PA, di Tomaso E, Muzikansky A, Barker FG, Stemmer-Rachamimov A, Plotkin SR. Bevacizumab Treatment for Meningiomas in NF2: A Retrospective Analysis of 15 Patients. PLoS One. 2013; 8(3):e59941.
    View in: PubMed
  2. Plotkin SR, Blakeley JO, Evans DG, Hanemann CO, Hulsebos TJ, Hunter-Schaedle K, Kalpana GV, Korf B, Messiaen L, Papi L, Ratner N, Sherman LS, Smith MJ, Stemmer-Rachamimov AO, Vitte J, Giovannini M. Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria. Am J Med Genet A. 2013 Mar; 161(3):405-16.
    View in: PubMed
  3. van Eeghen AM, Pulsifer MB, Merker VL, Neumeyer AM, van Eeghen EE, Thibert RL, Cole AJ, Leigh FA, Plotkin SR, Thiele EA. Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approach. Dev Med Child Neurol. 2013 Feb; 55(2):146-53.
    View in: PubMed
  4. Dunn GP, Spiliopoulos K, Plotkin SR, Hornicek FJ, Harmon DC, Delaney TF, Williams Z. Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis Type 1. J Neurosurg. 2013 Jan; 118(1):142-8.
    View in: PubMed
  5. Wirth LJ, Plotkin SR, Emerick KS, Cunnane ME, Faquin WC. Case records of the Massachusetts General Hospital. Case 29-2012. A 49-year-old man with pain and cranial-nerve palsies after treatment of oral cancer. N Engl J Med. 2012 Sep 20; 367(12):1136-47.
    View in: PubMed
  6. Smith MJ, Walker JA, Shen Y, Stemmer-Rachamimov A, Gusella JF, Plotkin SR. Expression of SMARCB1 (INI1) mutations in familial schwannomatosis. Hum Mol Genet. 2012 Dec 15; 21(24):5239-45.
    View in: PubMed
  7. Merker VL, Esparza S, Smith MJ, Stemmer-Rachamimov A, Plotkin SR. Clinical features of schwannomatosis: a retrospective analysis of 87 patients. Oncologist. 2012; 17(10):1317-22.
    View in: PubMed
  8. Wang DL, Smith KB, Esparza S, Leigh FA, Muzikansky A, Park ER, Plotkin SR. Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome. Genet Med. 2012 Dec; 14(12):977-82.
    View in: PubMed
  9. Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol. 2012 Aug; 33(6):1046-52.
    View in: PubMed
  10. Vakharia KT, Henstrom D, Plotkin SR, Cheney M, Hadlock TA. Facial reanimation of patients with neurofibromatosis type 2. Neurosurgery. 2012 Jun; 70(2 Suppl Operative):237-43.
    View in: PubMed
  11. Plotkin SR, Bredella MA, Cai W, Kassarjian A, Harris GJ, Esparza S, Merker VL, Munn LL, Muzikansky A, Askenazi M, Nguyen R, Wenzel R, Mautner VF. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS One. 2012; 7(4):e35711.
    View in: PubMed
  12. Terry AR, Barker FG, Leffert L, Bateman BT, Souter I, Plotkin SR. Outcomes of hospitalization in pregnant women with CNS neoplasms: a population-based study. Neuro Oncol. 2012 Jun; 14(6):768-76.
    View in: PubMed
  13. Terry AR, Plotkin SR. Chemotherapy:: present and future. Otolaryngol Clin North Am. 2012 Apr; 45(2):471-86.
    View in: PubMed
  14. Hagel C, Stemmer-Rachamimov AO, Bornemann A, Schuhmann M, Nagel C, Huson S, Evans DG, Plotkin S, Matthies C, Kluwe L, Mautner VF. Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2-associated gliomas to be spinal ependymomas. Neuropathology. 2012 Dec; 32(6):611-6.
    View in: PubMed
  15. Uhlmann EJ, Plotkin SR. Neurofibromatoses. Adv Exp Med Biol. 2012; 724:266-77.
    View in: PubMed
  16. Jaremko JL, MacMahon PJ, Torriani M, Merker VL, Mautner VF, Plotkin SR, Bredella MA. Whole-body MRI in neurofibromatosis: incidental findings and prevalence of scoliosis. Skeletal Radiol. 2012 Aug; 41(8):917-23.
    View in: PubMed
  17. Blakeley JO, Evans DG, Adler J, Brackmann D, Chen R, Ferner RE, Hanemann CO, Harris G, Huson SM, Jacob A, Kalamarides M, Karajannis MA, Korf BR, Mautner VF, McClatchey AI, Miao H, Plotkin SR, Slattery W, Stemmer-Rachamimov AO, Welling DB, Wen PY, Widemann B, Hunter-Schaedle K, Giovannini M. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A. 2012 Jan; 158A(1):24-41.
    View in: PubMed
  18. Plotkin SR, O'Donnell CC, Curry WT, Bove CM, MacCollin M, Nunes FP. Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients. J Neurosurg Spine. 2011 Apr; 14(4):543-7.
    View in: PubMed
  19. di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi L, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, Hedley-Whyte ET, Sorensen AG, Batchelor TT, Jain RK. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res. 2011 Jan 1; 71(1):19-28.
    View in: PubMed
  20. Jeyaretna DS, Curry WT, Batchelor TT, Stemmer-Rachamimov A, Plotkin SR. Exacerbation of cerebral radiation necrosis by bevacizumab. J Clin Oncol. 2011 Mar 1; 29(7):e159-62.
    View in: PubMed
  21. Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, Xu L, Duda DG, Wen PY, Jain RK, Batchelor TT. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol. 2011 Jun; 103(2):325-32.
    View in: PubMed
  22. Plotkin SR, Halpin C, McKenna MJ, Loeffler JS, Batchelor TT, Barker FG. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol. 2010 Sep; 31(7):1135-43.
    View in: PubMed
  23. Miriam J. Smith and Scott R. Plotkin. Neurofibromatosis and Schwannomatosis. The MGH Guide to Clinical Cancer Genetics (eds., DC Chung and DA Haber). 2010; in press.
  24. Fabio P. Nunes, Scott R. Plotkin, Anat Stemmer-Rachamimov. Histopathology and Molecular Pathogenesis of Schwannomas. Principles and Practices of Neuro-Oncology: A Multidisciplinary Approach (Mehta, Chang, Vogelbaum, Guha, et al., Editors). 2010; in press.
  25. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010 Jun 10; 28(17):2817-23.
    View in: PubMed
  26. Wong HK, Lahdenranta J, Kamoun WS, Chan AW, McClatchey AI, Plotkin SR, Jain RK, di Tomaso E. Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res. 2010 May 1; 70(9):3483-93.
    View in: PubMed
  27. R Cavaliere, B O’Neill, S Plotkin, G van Imhoff, E Neuwelt, K Jahnke, L Abrey, T Batchelor, G Illerhaus, S Horning, G Petroni, B Lopes, and D Schiff. Primary CNS Post-Transplant Lymphoproliferative Disorder: The International PCNSL Collaborative Group Experience. Cancer. 2009; in press.
  28. El-Jawahri A, Podgurski LM, Eichler AF, Plotkin SR, Temel JS, Mitchell SL, Chang Y, Barry MJ, Volandes AE. Use of video to facilitate end-of-life discussions with patients with cancer: a randomized controlled trial. J Clin Oncol. 2010 Jan 10; 28(2):305-10.
    View in: PubMed
  29. Shen Y, Nunes F, Stemmer-Rachamimov A, James M, Mohapatra G, Plotkin S, Betensky RA, Engler DA, Roy J, Ramesh V, Gusella JF. Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas. BMC Med Genomics. 2009; 2:42.
    View in: PubMed
  30. Plotkin SR, Stemmer-Rachamimov AO, Barker FG, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009 Jul 23; 361(4):358-67.
    View in: PubMed
  31. James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov AO, Gusella JF, Ramesh V. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol. 2009 Aug; 29(15):4250-61.
    View in: PubMed
  32. Plotkin SR, Halpin C, Blakeley JO, Slattery WH, Welling DB, Chang SM, Loeffler JS, Harris GJ, Sorensen AG, McKenna MJ, Barker FG. Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J Neurooncol. 2009 May; 93(1):61-77.
    View in: PubMed
  33. Smith MJ, Boyd CD, MacCollin MM, Plotkin SR. Identity analysis of schwannomatosis kindreds with recurrent constitutional SMARCB1 (INI1) alterations. Clin Genet. 2009 May; 75(5):501-2.
    View in: PubMed
  34. Cai W, Kassarjian A, Bredella MA, Harris GJ, Yoshida H, Mautner VF, Wenzel R, and Plotkin SR. Determination of Tumor Burden in NF1, NF2, and Schwannomatosis on Whole Body MR Images. Radiology. 2009; 250(3):665-73.
  35. Cai W, Kassarjian A, Bredella MA, Harris GJ, Yoshida H, Mautner VF, Wenzel R, Plotkin SR. Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images. Radiology. 2009 Mar; 250(3):665-73.
    View in: PubMed
  36. Lu-Emerson C, Plotkin SR. The neurofibromatoses. Part 2: NF2 and schwannomatosis. Rev Neurol Dis. 2009; 6(3):E81-6.
    View in: PubMed
  37. Lu-Emerson C, Plotkin SR. The Neurofibromatoses. Part 1: NF1. Rev Neurol Dis. 2009; 6(2):E47-53.
    View in: PubMed
  38. McQueen M, MacCollin M, Gusella J, Plotkin SR. Patient and physician attitudes regarding clinical trials in neurofibromatosis 1. J Neurosci Nurs. 2008 Dec; 40(6):341-5.
    View in: PubMed
  39. David Reardon, Karen Fink, Tom Mikkelsen, Timothy Cloughesy, Alison O'Neill, Scott Plotkin, Michael Glantz, Paula Ravin, Jeffrey Raizer, Keith Rich, David Schiff, William Shapiro, Susan Burdette-Radoux, Edward Dropcho, Sabine Wittemer, Johannes Nippgen, Martin Picard, Louis Nabors. Activity of Cilengitide, an Integrin-Targeting RGD Peptide, Among Adults with Recurrent Glioblastoma Multiforme: Results of a Randomized Phase 2 Study. J Clin Oncol. 2008; 26(34):5610-5617.
  40. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M, Nabors LB. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008 Dec 1; 26(34):5610-7.
    View in: PubMed
  41. S.R. Plotkin. Phakomatoses: Neurofibromatosis 2. In Larry R. Squire, Editor-in-Chief, The New Encyclopedia of Neuroscience. 2008.
  42. Boyd C, Smith MJ, Kluwe L, Balogh A, Maccollin M, Plotkin SR. Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis. Clin Genet. 2008 Oct; 74(4):358-66.
    View in: PubMed
  43. Eichler AF, Plotkin SR. Brain metastases. Curr Treat Options Neurol. 2008 Jul; 10(4):308-14.
    View in: PubMed
  44. Plotkin SR, Singh MA, O'Donnell CC, Harris GJ, McClatchey AI, Halpin C. Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy. Nat Clin Pract Oncol. 2008 Aug; 5(8):487-91.
    View in: PubMed
  45. Harris GJ, Plotkin SR, Maccollin M, Bhat S, Urban T, Lev MH, Slattery WH. Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II. Neurosurgery. 2008 Jun; 62(6):1314-9; discussion 1319-20.
    View in: PubMed
  46. Scott Randall Plotkin. Neurofibromatosis type 2 and related disorders. Ruggieri M, Pascual-Castroviejo I, and DiRocco C, editors. Neurocutaneous Disorders: Phakomatoses and Hamartoneoplastic Sydnromes. 2008; 153-180.
  47. Wendell LC, Freeman SH, Plotkin SR, Sims JR. Clinical reasoning: a case of multiple intracerebral hemorrhages. Neurology. 2007 Dec 4; 69(23):E30-4.
    View in: PubMed
  48. Farrell CJ, Plotkin SR. Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel-Lindau, and other syndromes. Neurol Clin. 2007 Nov; 25(4):925-46, viii.
    View in: PubMed
  49. Chu-Shore C and Plotkin SR. The Phakomatoses. Rosenberg RN, DiMauro S, Paulson H, Ptacek L, Nestler E, editors. The molecular and genetic basis of neurological and psychiatric disease. 2007.
  50. Bredella MA, Torriani M, Hornicek F, Ouellette HA, Plamer WE, Williams Z, Fischman AJ, Plotkin SR. Value of PET in the assessment of patients with neurofibromatosis type 1. AJR Am J Roentgenol. 2007 Oct; 189(4):928-35.
    View in: PubMed
  51. James MF, Lelke JM, Maccollin M, Plotkin SR, Stemmer-Rachamimov AO, Ramesh V, Gusella JF. Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth. Neurobiol Dis. 2008 Feb; 29(2):278-92.
    View in: PubMed
  52. Alcalay RN, Shulman JM, Plotkin SR. Ramsay Hunt syndrome in a patient with metastatic lung cancer to brain. J Neurooncol. 2008 Jan; 86(1):55-6.
    View in: PubMed
  53. Greer DM, Schaefer PW, Plotkin SR, Hasserjian RP, Steere AC. Case records of the Massachusetts General Hospital. Case 11-2007. A 59-year-old man with neck pain, weakness in the arms, and cranial-nerve palsies. N Engl J Med. 2007 Apr 12; 356(15):1561-70.
    View in: PubMed
  54. Plotkin SR and Grier JT. Increased intracranial pressure and extradural compression syndromes. In: Baehring JM and Piepmeier JM, editors. Brain tumors: practical guide to diagnosis and treatment. 2007; 89:427-446.
  55. Scott Plotkin, M.D., Ph.D. About Neurofibromatosis 2. 2007.
  56. Fitzsimmons AL and Plotkin SR. Metastatic brain tumors. In: Longo D, Chabner B, and Lynch T, editors. Harrison's Handbook of Oncology. 2007.
  57. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007 Jan; 11(1):83-95.
    View in: PubMed
  58. Plotkin SR. Update on primary central nervous system lymphoma. Curr Opin Neurol. 2005 Dec; 18(6):645-53.
    View in: PubMed
  59. Mrugala MM, Batchelor TT, Plotkin SR. Peripheral and cranial nerve sheath tumors. Curr Opin Neurol. 2005 Oct; 18(5):604-10.
    View in: PubMed
  60. MacCollin M, Chiocca EA, Evans DG, Friedman JM, Horvitz R, Jaramillo D, Lev M, Mautner VF, Niimura M, Plotkin SR, Sang CN, Stemmer-Rachamimov A, Roach ES. Diagnostic criteria for schwannomatosis. Neurology. 2005 Jun 14; 64(11):1838-45.
    View in: PubMed
  61. Plotkin SR, Dorfman MV, Loeffler JS. Facial numbness in a man with inguinal and retroperitoneal masses. Nat Clin Pract Oncol. 2005 Jan; 2(1):54-8; quiz 1 p following 58.
    View in: PubMed
  62. Plotkin SR, Betensky RA, Hochberg FH, Grossman SA, Lesser GJ, Nabors LB, Chon B, Batchelor TT. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res. 2004 Sep 1; 10(17):5643-6.
    View in: PubMed
  63. Plotkin SR, Wen PY. Neurologic complications of cancer therapy. In: Wen PY, Glanz MJ, editors. Neurologic Clinics: Neurologic Complications of Cancer. 2003; 21(1):279-318.
  64. Plotkin SR, Wen PY. Neurologic complications of cancer therapy. Neurol Clin. 2003 Feb; 21(1):279-318, x.
    View in: PubMed
  65. Plotkin SR, Batchelor TT. Primary nervous system lymphoma. Curr Treat Options Oncol. 2002 Dec; 3(6):525-35.
    View in: PubMed
  66. Plotkin SR, Wen PY. Brain metastases. Office Practice of Neurology. 2002.
  67. Plotkin SR, Ning MM. Traumatic cervical spine disruption. N Engl J Med. 2001 Oct 11; 345(15):1134-5.
    View in: PubMed
  68. Plotkin SR, Batchelor TT. Primary nervous-system lymphoma. Lancet Oncol. 2001 Jun; 2(6):354-65.
    View in: PubMed
  69. Plotkin SR, Batchelor TT. Advances in the therapy of primary central nervous system lymphoma. Clin Lymphoma. 2001 Mar; 1(4):263-75; discussion 276-7.
    View in: PubMed
  70. Plotkin SR, Banks WA, Cohn CS, Kastin AJ. Withdrawal from alcohol in withdrawal seizure-prone and -resistant mice: evidence for enkephalin resistance. Pharmacol Biochem Behav. 2001 Mar; 68(3):379-87.
    View in: PubMed
  71. Plotkin SR, Banks WA, Maness LM, Kastin AJ. Differential transport of rat and human interleukin-1alpha across the blood-brain barrier and blood-testis barrier in rats. Brain Res. 2000 Oct 20; 881(1):57-61.
    View in: PubMed
  72. Plotkin SR, Post R. Folk remedy use in the inner city. South Med J. 1999 Aug; 92(8):795-8.
    View in: PubMed
  73. Plotkin SR, Banks WA, Kastin AJ. Enkephalin, PPE mRNA, and PTS-1 in alcohol withdrawal seizure-prone and -resistant mice. Alcohol. 1998 Jan; 15(1):25-31.
    View in: PubMed
  74. Ramsey AH, Steinmann WC, Capps A, Diaz A, Netland K, Plotkin S, Wuttke J. St. Thomas Immunization Initiative. A student-run community action project. J La State Med Soc. 1997 Jun; 149(6):197-9.
    View in: PubMed
  75. Plotkin SR, Banks WA, Waguespack PJ, Kastin AJ. Ethanol alters the concentration of Met-enkephalin in brain by affecting peptide transport system-1 independent of preproenkephalin mRNA. J Neurosci Res. 1997 May 1; 48(3):273-80.
    View in: PubMed
  76. SR Plotkin. Regulation of met-enkephalin in animal models of alcoholism. 1997.
  77. Plotkin SR, Banks WA, Kastin AJ. Comparison of saturable transport and extracellular pathways in the passage of interleukin-1 alpha across the blood-brain barrier. J Neuroimmunol. 1996 Jun; 67(1):41-7.
    View in: PubMed
  78. Banks WA, Plotkin SR, Kastin AJ. Permeability of the blood-brain barrier to soluble cytokine receptors. Neuroimmunomodulation. 1995 May-Jun; 2(3):161-5.
    View in: PubMed
  79. Banks WA, Ortiz L, Plotkin SR, Kastin AJ. Human interleukin (IL) 1 alpha, murine IL-1 alpha and murine IL-1 beta are transported from blood to brain in the mouse by a shared saturable mechanism. J Pharmacol Exp Ther. 1991 Dec; 259(3):988-96.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Plotkin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (333) concept(s)
_
Co-Authors
See all (76) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_